Hilary Eaton is the Chief Business Officer of Profluent Bio. She is a rare disease patient-advocate passionate about developing next-generation genetic medicines to cure monogenic disorders, with more than a decade driving partnerships at leading gene editing companies, including Editas, Vor, and Tome.
Prior to her career in business development, Hilary received her PhD from Duke University and completed a postdoc at Harvard Medical School and Dana-Farber Cancer Institute.
Her daughter was recently diagnosed with Okur-Chung Neurodevelopmental Syndrome, and Hilary hopes to mesh professional and personal interests in support of the groundbreaking work ongoing at the CSNK2A1 Foundation.